<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241279</url>
  </required_header>
  <id_info>
    <org_study_id>657</org_study_id>
    <nct_id>NCT01241279</nct_id>
  </id_info>
  <brief_title>Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses</brief_title>
  <official_title>A Two Arm Prospective, Randomized, Double-Masked Clinical Evaluation of Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the correlation of near vision and changes in
      higher order aberrations following lens extraction and to characterize the defocus curves of
      Crystalens® AO™ intraocular lens (IOL) versus the monofocal aspheric SofPort® LI61AO IOL in
      adults.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low enrollment
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude of Accommodation</measure>
    <time_frame>Visit 4 (postoperative day 120-180)</time_frame>
    <description>The measurement of optical change in the power of the eye when viewing from far to near. Accommodation decreases as age increases resulting in an inability to focus on near objects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>All visits through visit 4 (day 160-180)</time_frame>
    <description>Number of correct letters on an early treatment diabetic retinopathy study (ETDRS) chart to measure distance visual acuity and the smallest readable print size on an Minnesota Low-Vision Reading (MNREAD) acuity chart for intermediate and near visual acuity (VA). Visual acuity measured in LogMAR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Crystalens AO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A silicone multi-piece accommodating intraocular lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoftPort LI61AO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A silicone multi-piece foldable aspheric intraocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crystalens AO</intervention_name>
    <description>Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.</description>
    <arm_group_label>Crystalens AO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SoftPort LI61AO</intervention_name>
    <description>Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.</description>
    <arm_group_label>SoftPort LI61AO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have clear intraocular media other than cataract.

          -  Subjects must have a clinically documented diagnosis of age-related bilateral
             cataracts that are considered amenable to treatment with standard phacoemulsification
             cataract extraction.

          -  Subjects must be undergoing primary IOL implantation for the correction of aphakia
             following central continuous curvilinear anterior capsulorrhexis and
             phacoemulsification cataract extraction.

          -  Subjects must require a spherical lens power from 10.00 D to 30.00 D.

          -  Subjects must be willing and able to return for all scheduled follow-up examinations
             for each eye from days 1 through 180 following surgery.

          -  Subjects must have ≤ 1.25 D of preoperative corneal astigmatism.

        Exclusion Criteria:

          -  Subjects with corneal pathology potentially affecting topography.

          -  Subjects whose fundus cannot be assessed preoperatively.

          -  Subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or
             other retinal disorders) that cause potential acuity losses to a level worse than
             20/30 as verified by OCT.

          -  Subjects with conditions with increased risk of zonular rupture, such as
             pseudoexfoliation syndrome.

          -  Subjects who have any active inflammation or edema (swelling) of the cornea, including
             but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis.

          -  Subjects with uncontrolled glaucoma.

          -  Subjects with previous retinal detachment.

          -  Subjects with visually significant diabetic retinopathy (proliferative or
             non-proliferative) which reduces potential acuity to 20/30 or worse.

          -  Subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract.

          -  Subjects with marked microphthalmos or aniridia.

          -  Subjects who have had previous corneal surgery.

          -  Subjects with irregular corneal astigmatism.

          -  Subjects with amblyopia which reduces potential acuity to worse than 20/30.

          -  Subjects with optic atrophy.

          -  Subjects with iris neovascularization.

          -  Subjects with clinically significant retinal pigment epithelium/macular changes which
             reduces potential acuity to 20/30 or worse.

          -  Subjects with chronic use of systemic steroids or immunosuppressive medications.

          -  Subjects lacking intact binocular vision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson Varughese</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals/Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>May 17, 2013</results_first_submitted>
  <results_first_submitted_qc>November 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cataract surgery</keyword>
  <keyword>intraocular lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 6 subjects (11 eyes) were enrolled at one investigational site in the US. First participant enrolled 10/26/2010; last participant visit 12/01/2011.</recruitment_details>
      <pre_assignment_details>Due to the small sample size, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS CAN BE MADE.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Crystalens AO</title>
          <description>A silicone multi-piece accommodating intraocular lens</description>
        </group>
        <group group_id="P2">
          <title>SoftPort LI61AO</title>
          <description>A silicone multi-piece foldable aspheric intraocular lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crystalens AO</title>
          <description>A silicone multi-piece accommodating intraocular lens</description>
        </group>
        <group group_id="B2">
          <title>SoftPort LI61AO</title>
          <description>A silicone multi-piece foldable aspheric intraocular lens</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age 54 to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amplitude of Accommodation</title>
        <description>The measurement of optical change in the power of the eye when viewing from far to near. Accommodation decreases as age increases resulting in an inability to focus on near objects.</description>
        <time_frame>Visit 4 (postoperative day 120-180)</time_frame>
        <population>DUE TO THE SMALL SAMPLE SIZE, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS CAN BE MADE.</population>
        <group_list>
          <group group_id="O1">
            <title>Crystalens AO</title>
            <description>A silicone multi-piece accommodating intraocular lens</description>
          </group>
          <group group_id="O2">
            <title>SoftPort LI61AO</title>
            <description>A silicone multi-piece foldable aspheric intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Amplitude of Accommodation</title>
          <description>The measurement of optical change in the power of the eye when viewing from far to near. Accommodation decreases as age increases resulting in an inability to focus on near objects.</description>
          <population>DUE TO THE SMALL SAMPLE SIZE, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS CAN BE MADE.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>Number of correct letters on an early treatment diabetic retinopathy study (ETDRS) chart to measure distance visual acuity and the smallest readable print size on an Minnesota Low-Vision Reading (MNREAD) acuity chart for intermediate and near visual acuity (VA). Visual acuity measured in LogMAR.</description>
        <time_frame>All visits through visit 4 (day 160-180)</time_frame>
        <population>DUE TO THE SMALL SAMPLE SIZE, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS CAN BE MADE.</population>
        <group_list>
          <group group_id="O1">
            <title>Crystalens AO</title>
            <description>A silicone multi-piece accommodating intraocular lens</description>
          </group>
          <group group_id="O2">
            <title>SoftPort LI61AO</title>
            <description>A silicone multi-piece foldable aspheric intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Number of correct letters on an early treatment diabetic retinopathy study (ETDRS) chart to measure distance visual acuity and the smallest readable print size on an Minnesota Low-Vision Reading (MNREAD) acuity chart for intermediate and near visual acuity (VA). Visual acuity measured in LogMAR.</description>
          <population>DUE TO THE SMALL SAMPLE SIZE, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS CAN BE MADE.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Crystalens AO</title>
          <description>A silicone multi-piece accommodating intraocular lens</description>
        </group>
        <group group_id="E2">
          <title>SoftPort LI61AO</title>
          <description>A silicone multi-piece foldable aspheric intraocular lens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to lack of enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Johnson Varughese</name_or_title>
      <organization>Valeant Pharmaceuticals/Bausch &amp; Lomb</organization>
      <phone>908-927-1162</phone>
      <email>Johnson.Varughese@valeant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

